AUG 25, 2020 10:25 AM PDT

FDA Approves Cannabis Drug to Treat Rare Genetic Disease

WRITTEN BY: Annie Lennon

The US Food and Drug Administration has approved Epidiolex, a cannabidiol (CBD) oral solution, to treat seizures linked to tuberous sclerosis complex (TSC), a rare genetic disease that causes benign tumors to grow on the brain and other organs such as the eyes, heart, and lungs.

Occurring in around 1 in 6,000 people, TSC typically affects the central nervous system. Aside from seizures, it is also known to cause developmental delay and behavioral problems. 

Previously, Epidolex had been approved to treat seizures from two rare forms of epilepsy: Lennox-Gestaut syndrome (LGS) and Dravet syndrome (DS). It is also currently the only FDA-approved drug to contain a purified substance derived from cannabis.

Prior to approval, Epidolex underwent a randomized, double-blind, placebo-controlled trial where 148 patients out of 224 received the drug. The purpose of the study was to measure the difference from baseline in seizure frequency. 

In the end, the researchers found that patients treated with Epidolex had a significant reduction in the frequency of seizures during the treatment periods than those on the placebo. The effects were seen within eight weeks and remained throughout the 16-week treatment period. 

The most common side effects form the drug in patients with TSC included diarrhea, elevated liver enzymes, decreased appetite, fever, sleepiness, and vomiting. Less common side effects for patients, regardless of condition, include liver injury, reduced weight, anemia, and increased creatinine, a sign of impaired kidney function.  

Given its potential for negative side effects (findings from a human trial showing that between 5% and 20% of patients receiving the drug suffered from liver damage), extreme care is needed for those who take it. As such, after prescription by a physician, parents, caregivers, and families are advised to monitor any unusual changes in mood or behavior, including worsening depression and suicidal thoughts, among those taking the drug. 

 

Sources: LabRootsMedical News

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUL 26, 2020
Cannabis Sciences
Medicinal Cannabis Kills Cancer Cells
JUL 26, 2020
Medicinal Cannabis Kills Cancer Cells
Researchers at the University of Newcastle have found that a modified version of medicinal cannabis can kill and inhibit ...
AUG 10, 2020
Cannabis Sciences
Researchers Debunk Cannabis Growing Myths
AUG 10, 2020
Researchers Debunk Cannabis Growing Myths
Researchers at Utah State University grew cannabis to study until the Controlled Substances Act came into force in 1970. ...
AUG 25, 2020
Cannabis Sciences
Synthetic Cannabinoid Drug to Enter Human Trials
AUG 25, 2020
Synthetic Cannabinoid Drug to Enter Human Trials
In recent months, interest has been growing in the potential for cannabinoids- the compounds found in cannabis- to treat ...
SEP 21, 2020
Cannabis Sciences
Why Do We Build Tolerance to Cannabis?
SEP 21, 2020
Why Do We Build Tolerance to Cannabis?
Many notice that after regularly smoking cannabis, it takes more and more to feel its effects- if any at all. While abst ...
OCT 12, 2020
Cannabis Sciences
Can Cannabis Relieve Symptoms of Down Syndrome?
OCT 12, 2020
Can Cannabis Relieve Symptoms of Down Syndrome?
Increasing anecdotal and academic evidence has been emerging in recent years about the plethora of health benefits behin ...
NOV 07, 2020
Cannabis Sciences
Does Cannabis Make Bipolar Disorder Better or Worse?
NOV 07, 2020
Does Cannabis Make Bipolar Disorder Better or Worse?
While anecdotal evidence and some case studies suggest cannabis may benefit those with bipolar disorder, studies have re ...
Loading Comments...